Pegpleranib
Identification
- Generic Name
- Pegpleranib
- DrugBank Accession Number
- DB06325
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Synonyms
- Pegpleranib
Pharmacology
- Indication
Investigated for use/treatment in macular degeneration and eye disorders/infections.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
E10030 is an aptamer based, anti-platelet-derived growth factor (PDGF) which inhibits PDGF-B with high specificity and affinity. E10030 may be efficacious in treating neovascular age-related macular degeneration when combined with a vascular endothelial growth factor A (VEGF-A) inhibitor. PDGF-B is implicated in vascular stability and function through its role in activating the recruitment of mural cells (pericytes) by endothelial cells to envelop the developing vasculature. Pericyte recruitment is part of the maturation process in blood vessel development and pericytes act as support cells for mature blood vessels. [Opthotech Corp. Website] Neovascular age-related macular degeneration is a condition where new, extremely fragile blood vessels under the retina where they burst and cause damage to surrounding tissue, resulting in vision problems.
Target Actions Organism UPlatelet-derived growth factor subunit B Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAntihemophilic factor (recombinant), PEGylated The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Pegpleranib. Certolizumab pegol The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Pegpleranib. Damoctocog alfa pegol The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Pegpleranib. Elapegademase The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegpleranib. Lipegfilgrastim The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Pegpleranib. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Pegpleranib sodium DD50D2QKH1 1449390-73-1 Not applicable
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- VER541H6NK
- CAS number
- 1618657-13-8
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
- General References
- Moore MS, Blobel G: The two steps of nuclear import, targeting to the nuclear envelope and translocation through the nuclear pore, require different cytosolic factors. Cell. 1992 Jun 12;69(6):939-50. [Article]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Terminated Treatment Age - Related Macular Degeneration (AMD) 3 2 Completed Treatment Age - Related Macular Degeneration (AMD) 1 1 Completed Treatment Age - Related Macular Degeneration (AMD) 1 1, 2 Completed Treatment Von Hippel-Lindau Disease 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Superoxide-generating nadph oxidase activator activity
- Specific Function
- Growth factor that plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis. Potent mitogen for cells of mesenchymal origin. R...
- Gene Name
- PDGFB
- Uniprot ID
- P01127
- Uniprot Name
- Platelet-derived growth factor subunit B
- Molecular Weight
- 27283.19 Da
Drug created at March 19, 2008 16:24 / Updated at February 21, 2021 18:52